News in multiple sclerosis: Remyelination as a therapeutic target

Med Clin (Barc). 2017 Apr 21;148(8):377-380. doi: 10.1016/j.medcli.2016.10.021. Epub 2016 Dec 4.

[Article in English, Spanish]

Authors

Jorge Matías-Guiu¹, Ulises Gomez-Pinedo², Jordi A Matias-Guiu²

Affiliations

¹ Servicio de Neurología, Instituto de Neurociencias, Hospital Clínico San Carlos, Universidad Complutense, Instituto de Investigación Sanitaria San Carlos (idiSSC), Madrid, España. Electronic address: inc.hcsc@salud.madrid.org.
² Servicio de Neurología, Instituto de Neurociencias, Hospital Clínico San Carlos, Universidad Complutense, Instituto de Investigación Sanitaria San Carlos (idiSSC), Madrid, España.

PMID: 27923464
DOI: 10.1016/j.medcli.2016.10.021

No abstract available

Publication types

Review

MeSH terms

Humans
Immunologic Factors / pharmacology
Immunologic Factors / therapeutic use*
Multiple Sclerosis / diagnosis
Multiple Sclerosis / drug therapy*
Multiple Sclerosis / physiopathology
Peripheral Nervous System Agents / pharmacology
Peripheral Nervous System Agents / therapeutic use*
Remyelination / drug effects*

Substances

Immunologic Factors
Peripheral Nervous System Agents